Homology Medicines, Inc. (0T6G.L)
0T6G.L Stock Price Chart
Explore Homology Medicines, Inc. interactive price chart. Choose custom timeframes to analyze 0T6G.L price movements and trends.
0T6G.L Company Profile
Discover essential business fundamentals and corporate details for Homology Medicines, Inc. (0T6G.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
4 Oct 2018
Employees
28.00
CEO
Jodie Pope Morrison
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
0T6G.L Financial Timeline
Browse a chronological timeline of Homology Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 5 Nov 2025
Upcoming earnings on 6 Aug 2025
Earnings released on 8 May 2025
EPS came in at -$0.90 surpassing the estimated -$1.23 by +26.83%.
Earnings released on 11 Mar 2025
EPS came in at -$1.16 surpassing the estimated -$1.53 by +23.88%.
Earnings released on 7 Nov 2024
EPS came in at -$1.46 falling short of the estimated -$1.38 by -5.87%.
Earnings released on 8 Aug 2024
EPS came in at -$1.42 falling short of the estimated -$1.00 by -42.38%.
Earnings released on 9 May 2024
EPS came in at $0.32 surpassing the estimated -$1.42 by +122.56%.
Stock split effective on 27 Mar 2024
Shares were split 1:18, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2024
EPS came in at -$5.00 surpassing the estimated -$5.40 by +7.39%, while revenue for the quarter reached -$14.66M, missing expectations by -3.03K%.
Earnings released on 15 Nov 2023
EPS came in at -$10.25 falling short of the estimated -$7.56 by -35.62%.
Earnings released on 28 Jul 2023
EPS came in at -$10.91 falling short of the estimated -$8.51 by -28.33%, while revenue for the quarter reached $354.00K, missing expectations by -57.38%.
Earnings released on 12 May 2023
EPS came in at -$9.00 surpassing the estimated -$9.54 by +5.71%, while revenue for the quarter reached $802.00K, missing expectations by -20.95%.
Earnings released on 10 Mar 2023
EPS came in at -$10.74 falling short of the estimated -$8.86 by -21.21%, while revenue for the quarter reached $802.00K, missing expectations by -3.44%.
Earnings released on 30 Sept 2022
EPS came in at -$10.57 falling short of the estimated -$8.21 by -28.64%, while revenue for the quarter reached $802.00K, missing expectations by -6.81%.
Earnings released on 30 Jun 2022
EPS came in at -$9.12 surpassing the estimated -$9.68 by +5.70%, while revenue for the quarter reached $802.00K, missing expectations by -19.88%.
Earnings released on 4 May 2022
EPS came in at $28.65 surpassing the estimated -$8.87 by +423.09%, while revenue for the quarter reached $802.00K, missing expectations by -88.87%.
Dividend declared on 15 Mar 2022
A dividend of $0.02 per share was announced, adjusted to $0.29.
Earnings released on 9 Mar 2022
EPS came in at -$10.58 falling short of the estimated -$0.57 by -1.74K%, while revenue for the quarter reached $802.00K, missing expectations by -5.98%.
Earnings released on 15 Nov 2021
EPS came in at -$9.72, while revenue for the quarter reached $2.19M.
Earnings released on 30 Sept 2021
EPS came in at -$9.65, while revenue for the quarter reached $1.68M.
Earnings released on 31 Mar 2021
EPS came in at -$0.02, while revenue for the quarter reached $29.31M.
Earnings released on 31 Dec 2020
EPS came in at -$0.62, while revenue for the quarter reached $980.00K.
Earnings released on 30 Sept 2020
EPS came in at -$0.62, while revenue for the quarter reached $567.00K.
0T6G.L Stock Performance
Access detailed 0T6G.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.